AbbVie v Amgen: Is the “patent dance” fair for both sides?
Abbvie suing Amgen over its efforts to launch a Humira biosimilar is the first instance of parties not agreeing on which patents to be litigated under the BPCIA. The case poses the question of whether the patent dance strikes the right balance between parties
AbbVie filed for an injunction against Amgen in the District of Delaware on August 4, claiming that Amgen’s efforts to have a biosimilar version of AbbVie’s widely-used Humira drug infringe its patents.
The suit is the first...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.